News blog
US agency reverses stance on controversial diabetes drug
If ever there were a case study in the messy uncertainties of drug development, the diabetes drug Avandia (rosiglitazone) would be a prime candidate. On 25 November, US regulators removed safety restrictions that had been pasted on the drug in 2010 following concerns about heart risks. After years of debate and deliberation, Avandia can be marketed and prescribed freely again, even though, by now, sales of the drug have plummeted as people with diabetes turn to other options.
Recent comments on this blog
Experiments reveal that crabs and lobsters feel pain
US research ethics agency upholds decision on informed consent
Chemistry credit disputes under the spotlight
Chemistry credit disputes under the spotlight
Contamination created controversial ‘acid-induced’ stem cells